<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:35:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9296590" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9296590</identifier>
        <datestamp>2022-10-14</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3-mathml3.xsd" dtd-version="1.3" id="bcp15310" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2125</journal-id>
              <journal-id journal-id-type="publisher-id">BCP</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Clinical Pharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0306-5251</issn>
              <issn pub-type="epub">1365-2125</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9296590</article-id>
              <article-id pub-id-type="pmcid">PMC9296590</article-id>
              <article-id pub-id-type="pmc-uid">9296590</article-id>
              <article-id pub-id-type="pmid">35285974</article-id>
              <article-id pub-id-type="pmid">35285974</article-id>
              <article-id pub-id-type="doi">10.1111/bcp.15310</article-id>
              <article-id pub-id-type="publisher-id">BCP15310</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women</article-title>
                <alt-title alt-title-type="left-running-head">Tanaudommongkon et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="bcp15310-cr-0001" contrib-type="author">
                  <name>
                    <surname>Tanaudommongkon</surname>
                    <given-names>Asama</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0002" contrib-type="author">
                  <name>
                    <surname>Chaturvedula</surname>
                    <given-names>Ayyappa</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0003" contrib-type="author">
                  <name>
                    <surname>Hendrix</surname>
                    <given-names>Craig W.</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0004" contrib-type="author">
                  <name>
                    <surname>Fuchs</surname>
                    <given-names>Edward J.</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0005" contrib-type="author">
                  <name>
                    <surname>Shieh</surname>
                    <given-names>Eugenie</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0006" contrib-type="author">
                  <name>
                    <surname>Bakshi</surname>
                    <given-names>Rahul P.</given-names>
                  </name>
                  <xref rid="bcp15310-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15310-cr-0007" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Marzinke</surname>
                    <given-names>Mark A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1670-8786</contrib-id>
                  <xref rid="bcp15310-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="bcp15310-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>mmarzin1@jhmi.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="bcp15310-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">College of Pharmacy</named-content>
                <institution>University of North Texas Health Science Center</institution>
                <city>Fort Worth</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="bcp15310-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Clinical Pharmacology, Department of Medicine</named-content>
                <institution>Johns Hopkins University School of Medicine</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">MD</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="bcp15310-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pathology</named-content>
                <institution>Johns Hopkins University School of Medicine</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">MD</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mark A. Marzinke, Johns Hopkins University School of Medicine, 1800 Orleans Street, Sheikh Zayed Tower, B1020F, Baltimore, MD, USA.<break/>
Email: <email>mmarzin1@jhmi.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>88</volume>
              <issue seq="130">8</issue>
              <issue-id pub-id-type="doi">10.1111/bcp.v88.8</issue-id>
              <fpage>3674</fpage>
              <lpage>3682</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>07</day>
                  <month>2</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>07</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 The British Pharmacological Society-->
                <copyright-statement content-type="article-copyright">Â© 2022 The Authors. <italic toggle="yes">British Journal of Clinical Pharmacology</italic> published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is nonâcommercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:BCP-88-3674.pdf"/>
              <abstract>
                <sec id="bcp15310-sec-0001">
                  <title>Aims</title>
                  <p>Transgender women (TGW) have been underrepresented in trials and use genderâaffirming hormonal therapies (GAHT) that may alter renal function by significantly increasing creatinine clearance. Population pharmacokinetic (popPK) models and simulations would aid in understanding potential differences in emtricitabine/tenofovir disproxil fumarate (F/TDF) parentâmetabolite concentrations in TGW on GAHT when compared to cisgender men (CGM) not exposed to GAHT.</p>
                </sec>
                <sec id="bcp15310-sec-0002">
                  <title>Methods</title>
                  <p>Pharmacokinetic (PK) data from a Phase 1, openâlabel clinical trial with directly observed therapy of daily F/TDF consisting of 8 TGW and 8 CGM was utilized for model building. PopPK analysis was performed using nonlinear mixed effects modelling (NONMEM 7.5.0). Covariates of body weight, creatinine clearance, and gender were evaluated. Final models were subjected to Monte Carlo simulations to compare drug exposure following once daily and onâdemand (IPERGAY 2Â +Â 1Â +Â 1) dosing of F/TDF.</p>
                </sec>
                <sec id="bcp15310-sec-0003">
                  <title>Results</title>
                  <p>Tenofovir (TFV) and emtricitabine PK were best described by a 2âcompartment model, firstâorder absorption/elimination with absorption lag time. Parent models were linked to their metabolites by first order formation and elimination. Creatinine clearance was a significant covariate influencing clearance in both models. Simulations demonstrated that at least 2, weekly 2Â +Â 1Â +Â 1Â cycles of onâdemand dosing in TGW on GAHT is necessary for TFVâdiphosphate to reach similar exposure after the initial week of onâdemand dosing in CGM not on GAHT.</p>
                </sec>
                <sec id="bcp15310-sec-0004">
                  <title>Conclusion</title>
                  <p>PopPK models of TFV, emtricitabine and intracellular metabolites in TGW were established. Dose simulations revealed that TGW should be treated for at least 2 weeks to have comparable exposures to CGM.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="bcp15310-kwd-0001">HIV</kwd>
                <kwd id="bcp15310-kwd-0002">popPK model</kwd>
                <kwd id="bcp15310-kwd-0003">population pharmacokinetics</kwd>
                <kwd id="bcp15310-kwd-0004">preâexposure prophylaxis</kwd>
                <kwd id="bcp15310-kwd-0005">tenofovir, transgender women</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Clinical Pharmacology Training Grant</funding-source>
                  <award-id>T32 GM066691</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases
</institution>
                      <institution-id institution-id-type="doi">10.13039/100006492</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01 AI145675</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>Johns Hopkins Center for AIDS Research
</institution>
                      <institution-id institution-id-type="doi">10.13039/100017035</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30 AI042855</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="9"/>
                <word-count count="6797"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:07.10.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="bcp15310-cit-9001"><string-name><surname>Tanaudommongkon</surname><given-names>A</given-names></string-name>, <string-name><surname>Chaturvedula</surname><given-names>A</given-names></string-name>, <string-name><surname>Hendrix</surname><given-names>CW</given-names></string-name>, et al. <article-title>Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women</article-title>. <source>Br J Clin Pharmacol</source>. <year>2022</year>;<volume>88</volume>(<issue>8</issue>):<fpage>3674</fpage>â<lpage>3682</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.15310</pub-id>
<pub-id pub-id-type="pmid">35285974</pub-id></mixed-citation>
              </p>
              <fn-group>
                <fn id="bcp15310-note-1002">
                  <p><bold>Funding information</bold> Clinical Pharmacology Training Grant, Grant/Award Number: T32 GM066691; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Grant/Award Number: R01 AI145675; Johns Hopkins Center for AIDS Research, Grant/Award Number: P30 AI042855</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="bcp15310-body-0001">
            <boxed-text position="float" content-type="box" id="bcp15310-blk-0001">
              <sec id="bcp15310-sec-0006">
                <title>What is already known about this subject</title>
                <p>
                  <list list-type="bullet" id="bcp15310-list-0001">
                    <list-item id="bcp15310-li-0001">
                      <p>Transgender women (TGW) remain at highârisk for HIV infection.</p>
                    </list-item>
                    <list-item id="bcp15310-li-0002">
                      <p>The relationship between emtricitabine/tenofovir disoproxil fumarate (F/TDF) and genderâaffirming hormonal therapy (GAHT) is not completely understood.</p>
                    </list-item>
                    <list-item id="bcp15310-li-0003">
                      <p>Studies have shown lower plasma emtricitabine and tenofovir concentrations in TGW when compared to cisgender men (CGM).</p>
                    </list-item>
                  </list>
                </p>
              </sec>
              <sec id="bcp15310-sec-0007">
                <title>What this study adds</title>
                <p>
                  <list list-type="bullet" id="bcp15310-list-0002">
                    <list-item id="bcp15310-li-0004">
                      <p>A joint F/TDF parentâmetabolite population pharmacokinetic model in TGW on GAHT and CGM demonstrate that drug concentrations are influenced by renal function.</p>
                    </list-item>
                    <list-item id="bcp15310-li-0005">
                      <p>Simulations indicate that onâdemand F/TDF requires 2 weekly 2â+â1â+â1Â cycles in TGW on GAHT to achieve comparable tenofovirâmetabolite concentrations observed during a single 2â+â1â+â1Â cycle in CGM.</p>
                    </list-item>
                  </list>
                </p>
              </sec>
            </boxed-text>
            <sec id="bcp15310-sec-0008">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Transgender women (TGW) remain at highârisk for HIV infection, with an estimated global prevalence of 19%; they are 49âtimes more likely to acquire HIV than cisgender women of reproductive age.<xref rid="bcp15310-bib-0001" ref-type="bibr"><sup>1</sup></xref> TGW are a key population that would benefit from preâexposure prophylaxis (PrEP) for HIV prevention. However, there are barriers to PrEP uptake, including access to care, social stigma and patient concerns regarding the impact of PrEP on genderâaffirming hormonal therapies (GAHT).<xref rid="bcp15310-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="bcp15310-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="bcp15310-bib-0004" ref-type="bibr"><sup>4</sup></xref> TGW frequently access oestrogenâbased GAHT to induce physical changes and promote congruence with their gender identity; these therapies may also include antiâandrogenic agents.<xref rid="bcp15310-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="bcp15310-bib-0006" ref-type="bibr"><sup>6</sup></xref> The World Professional Association for Transgender Health has published transgenderâfocused recommendations to promote feminization and reduce gender dysphoria in TGW.<xref rid="bcp15310-bib-0007" ref-type="bibr"><sup>7</sup></xref> There is also heterogeneity in dosages and formulations of GAHT accessed by TGW. Given the variety in GAHT options available to TGW, in conjunction with existing concerns regarding unfavourable interactions between GAHT and PrEP regimens, more research is required in this area.</p>
              <p>Daily oral tenofovir disoproxil fumarate (TDF) 300âmg/emtricitabine (FTC) 200âmg (F/TDF) was the first drug regimen approved by the US Food and Drug Administration for PrEP. Daily product use was shown to be highly effective in reducing HIV acquisition; subsequent studies showed that an alternative <italic toggle="yes">onâdemand</italic> (IPERGAY 2â+â1â+â1) PrEP regimen in men who have sex with men is associated with an 86% relative risk reduction in HIV infection.<xref rid="bcp15310-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="bcp15310-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="bcp15310-bib-0010" ref-type="bibr"><sup>10</sup></xref> Earlier trials evaluating the efficacy of F/TDF demonstrated decreased PrEP efficacy and lower adherence in TGW in comparison to cisgender men (CGM) who have sex with men.<xref rid="bcp15310-bib-0009" ref-type="bibr"><sup>9</sup></xref> However, the relationship between F/TDF, and their active metabolites, tenofovirâdiphosphate (TFVâDP) and emtricitabineâtriphosphate (FTCâTP), and GAHT, is not completely understood. Two studies reported 24â32% lower TFV and FTC plasma concentrations in TGW when compared to contemporaneously studied CGM.<xref rid="bcp15310-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> However, Shieh <italic toggle="yes">et al</italic>. did not identify statistically significant differences in TFVâDP concentrations in peripheral blood mononuclear cells (PBMC) between populations<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref>; a similar finding was observed in a more recent study, which showed comparable intraerythrocytic TFVâDP concentrations collected as dried blood spots between CGM and TGW on stable GAHT.<xref rid="bcp15310-bib-0013" ref-type="bibr"><sup>13</sup></xref> Further, neither study found an impact of PrEP on GAHT.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> However, due to the variety and variability of analytical methods, as well as heterogeneity of GAHT regimens accessed among these studies, additional efforts to comprehensively assess the impact of GAHT on oral F/TDF for PrEP are warranted.</p>
              <p>Population pharmacokinetic (popPK) modelling is used to describe sources of PK parameter variability as well as their covariate relationships. PopPK models can facilitate clinical trial design, dose selection, and dose timing optimization. Numerous popPK studies describe the relationship between plasma TFV or FTC and PBMC TFVâDP or FTCâTP concentrations.<xref rid="bcp15310-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="bcp15310-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="bcp15310-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="bcp15310-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="bcp15310-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="bcp15310-bib-0019" ref-type="bibr"><sup>19</sup></xref> However, none of these studies include TGW on GAHT. In this report, we developed a joint parentâmetabolite model to characterize the interrelationship of plasma TFV/FTC with PBMC TFVâDP/FTCâTP in nonâHIVâinfected TGW and CGM based on data first reported in a descriptive noncompartmental analysis from our group.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> We then used the model to simulate a comparison of daily and onâdemand F/TDF PrEP in TGW on GAHT.</p>
            </sec>
            <sec sec-type="methods" id="bcp15310-sec-0009">
              <label>2</label>
              <title>METHODS</title>
              <sec id="bcp15310-sec-0010">
                <label>2.1</label>
                <title>Trial design</title>
                <p>The clinical study generating the data utilized in the popPK models and assay performance characteristics are described elsewhere.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> This analysis was approved by the North Texas Regional Institutional Review Board and the Johns Hopkins Medicine Institutional Review Board. Study data were collected between April 2016 and April 2018, and all participants provided informed consent to participate in the clinical study.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> Briefly, 8 TGW and 8 CGM were enrolled in a phase 1, openâlabel PK study of once daily TDF 300âmg/FTC 200âmg under direct observation in a research clinic for 8Â days. Study participants (CGM and TGW) were required to have a baseline creatinine clearance (CrCl)ââ¥70âmL/min, using the CockcroftâGault formula for inclusion in the clinical trial. Additional inclusion criteria for the protocol required TGW to be on oestrogenâbased GAHT with serum total oestradiol concentration &gt;100âpg/mL. GAHT consisting of oestrogen Â± progesterone or Â± antiandrogen medication were used by TGW in this cohort. After 7Â days of directly observed dosing, blood was collected predose, and 1, 2, 4, 6, 8 and 24âhours postdose, and PBMC were collected predose, and 2, 8 and 24âhours postdose.</p>
                <p>All doses of TDF and FTC and drug analyte concentrations were converted to micromolar units for comodelling. The intracellular metabolite concentrations were converted to micromolar units using 282âfL/cell as cellular volume.<xref rid="bcp15310-bib-0020" ref-type="bibr"><sup>20</sup></xref> The molecular weights used for conversion were: TDF, 635.52âg/mol; TFV, 287.216âg/mol; and FTC, 247.248âg/mol.</p>
              </sec>
              <sec id="bcp15310-sec-0011">
                <label>2.2</label>
                <title>PopPK model development</title>
                <p>PopPK analysis was performed using NONMEM (version 7.5.0, ICON Development Solution, Ellicott City, MD, USA) with Perl speaks NONMEM (PsN version 4.9.0) as an interface. R software (version 4.0.3) was used for dataset preparation and graphics. PopPK data analyses and subsequent simulations were performed between June 2020 and April 2021.</p>
                <p>Parent and metabolites were modelled simultaneously, in which plasma drug disposition was evaluated first, then the PBMC compartment was added to describe metabolite concentrations. Oneâ and 2â compartment models with firstâorder absorption, with and without a lag time, were tested for structural models. Metabolite compartments were linked to a firstâorder formation rate constant once a reasonable parent model was established. An exponential error model was used to describe interindividual variability, which was assumed to be normally distributed with mean of zero and variance of Ï<sup>2</sup>. Additional information on the popPK models may be found in <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">Supplemental File 1</xref>.</p>
                <p>For each analyte, additive, proportional, and combined additive and proportional residual variability models were assessed separately, and were assumed to be normally distributed with mean of zero and variance of 
<mml:math id="jats-math-1" display="inline"><mml:mi>Ï</mml:mi></mml:math>
<sup>2</sup>.</p>
                <p>Model selection was driven by a global evaluation based on NONMEM objective function value (OFV), the Akaike information criteria (AIC), successful convergence, goodnessâofâfit (GOF) plots, and precision and biological plausibility of parameter estimates. A decrease in the objective function by 3.84âunits (<italic toggle="yes">P</italic>â&lt;â.05, 1 degree of freedom) for hierarchical models was considered to be significant. For nonânested model comparisons, the AIC was used for model selection using the following formula: AICâ=âNONMEM OFVâ+â2*number of parameters in the model. A drop in AIC of 2 or more was a threshold for considering 1 model over another.<xref rid="bcp15310-bib-0021" ref-type="bibr"><sup>21</sup></xref>
</p>
                <p>For covariate screening, we used biological rationale, parameter <italic toggle="yes">vs</italic>. covariate scatterplots for continuous variables, and boxplots for categorical variables. Body weight, CrCl (estimated by CockcroftâGault equation using the female term for TGW), and selfâidentified gender were evaluated for the impact on PK parameters. Continuous covariates were modeled using a medianânormalized power model. Categorical covariate was modeled using a proportional model. We used forward inclusion and backward elimination procedures along with the likelihood ratio test to evaluate the effect of each covariate on model parameters. Covariates were considered significant and included in the basic model if the decrease in OFV was &gt;3.84âunits (<italic toggle="yes">P</italic>â&lt;â.05, 1 degree of freedom) for forward inclusion, and the increase in OFV was &gt;6.64âunits (<italic toggle="yes">P</italic>â&lt;â.01, 1 degree of freedom) for backward elimination.<xref rid="bcp15310-bib-0022" ref-type="bibr"><sup>22</sup></xref>
</p>
              </sec>
              <sec id="bcp15310-sec-0012">
                <label>2.3</label>
                <title>Model evaluation</title>
                <p>GOF plots, visual predictive checks (VPCs),<xref rid="bcp15310-bib-0023" ref-type="bibr"><sup>23</sup></xref> and nonparametric bootstrap analysis were utilized to evaluate the final models and parameter estimates.<xref rid="bcp15310-bib-0024" ref-type="bibr"><sup>24</sup></xref> GOF plots include individual (IPRED) and population (PRED) predictions <italic toggle="yes">vs</italic>. observed concentrations, and conditional weighted residuals (CWRES) <italic toggle="yes">vs</italic>. time after dose and PRED.<xref rid="bcp15310-bib-0025" ref-type="bibr"><sup>25</sup></xref> VPCs were conducted using PsN and R. A total of 500 replicates of the simulated dataset were produced from the final models and used for the determination of prediction intervals. The 5th, 50th and 95th percentiles of the simulated concentrations were plotted against the time after dose and compared with observed TFV, FTC, TFVâDP and FTCâTP. The nonparametric bootstrap method was performed to evaluate reliability and stability of the final models. Nonparametric bootstraps of 500 iterations were conducted to estimate 95% confidence intervals (CIs) for the population parameters.</p>
              </sec>
              <sec id="bcp15310-sec-0013">
                <label>2.4</label>
                <title>Monte Carlo simulations to compare onâdemand <italic toggle="no">vs</italic>. QD dosing regimen</title>
                <p>Monte Carlo simulations of plasma (TFV and FTC) and PBMC (TFVâDP and FTCâTP) were performed for 500 virtual subjects with gender specific CrCl using the final population PK models. For genderâspecific CrCl, random samples (<italic toggle="yes">n</italic>â=â500) of CrCl were generated from mean and standard deviation from the trial data using R. Four different dosing scenarios were simulated with respect to a sexual activity (potential exposure of virus) as a reference time point:</p>
                <p>Scenario 1: Subjects were on conventional daily dosing (F/TDF) before sexual exposure and at steady state, consistent with Food and Drug Administration label dosing</p>
                <p>Scenario 2: Subjects initiate conventional daily dosing on the day of sexual exposure to represent initial phase of conventional daily dosing</p>
                <p>Scenario 3: Onâdemand dosing in which subjects took a double dose 2Â hours before exposure followed by a single dose 24âhours after the first dose, and a single dose 24âhours after the second dose (1âcycle), consistent with the <italic toggle="yes">onâdemand</italic> IPERGAY 2â+â1â+â1 regimen. Onâdemand dosing is interchangeably referred to as 2â+â1â+â1 regimen in the remaining text.</p>
                <p>Scenario 4: Same as Scenario 3 but repeat the regimen for a total of 2 weeks (2âcycles)</p>
                <p>For each simulated scenario, a mean concentrationâtime profile and boxplot of C<sub>24</sub> (trough) concentrations for TFV/FTC/TFVâDP/FTCâTP after the exposure were compared.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="bcp15310-sec-0014">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="bcp15310-sec-0015">
                <label>3.1</label>
                <title>Data summary</title>
                <p>Demographic summary of the participants is shown in TableÂ <xref rid="bcp15310-tbl-0001" ref-type="table">1</xref>. A total of 179 concentration values from 16 subjects were available for the model building exercise. Most participants were Black (75%). TGW showed no differences in age or weight compared to CGM (<italic toggle="yes">P</italic>â&gt;â.05). There were statistically significant differences in serum creatinine and CrCl between genders (Pâ&lt;â.05), with TGW showing 24% lower creatinine and 61% higher CrCl when compared to CGM (FigureÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S1</xref>). These observations were not accounted for by a statistically nonsignificant 18% weight difference (<italic toggle="yes">P</italic>â&gt;â.05). No analyte concentrations were below the limit of quantification.</p>
                <table-wrap position="float" id="bcp15310-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Demographics of the participants</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">TGW (<italic toggle="no">n</italic>â=â8)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">CGM (<italic toggle="no">n</italic>â=â8)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="no">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, y<xref rid="bcp15310-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29 (27â38)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">46 (38â51)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">.195<xref rid="bcp15310-note-0002" ref-type="table-fn"><sup>b</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight, kg<xref rid="bcp15310-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">98 (85â113)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">83 (73â89)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">.130</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CrCl (mL/min)<xref rid="bcp15310-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">174 (117â184)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">108 (85â121)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">.038</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">SCr (mg/dL)<xref rid="bcp15310-note-0001" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.80 (0.80â0.83)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.05 (1.00â1.12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">.005</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Race</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">&gt;.999<xref rid="bcp15310-note-0003" ref-type="table-fn"><sup>c</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">African ancestry</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">European ancestry</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asian ancestry</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="bcp15310-ntgp-0001">
                    <fn id="bcp15310-note-0001">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Data expressed as median (interquartile range).</p>
                    </fn>
                    <fn id="bcp15310-note-0002">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Exact 2âsided <italic toggle="yes">P</italic> value, Wilcoxon rank sum test.</p>
                    </fn>
                    <fn id="bcp15310-note-0003">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Fisher's exact test.</p>
                    </fn>
                    <fn id="bcp15310-note-1003">
                      <p>Abbreviations: CGM, cisgender men; CrCl, creatinine clearance; SCr, serum creatinine; TGW, transgender women.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="bcp15310-sec-0016">
                <label>3.2</label>
                <title>PopPK model of FTC and FTCâTP</title>
                <p>Comparison of 1â and 2âcompartment models for plasma FTC using AIC and OFV confirmed that a 2âcompartment model provided a better fit and significantly smaller objective function (ÎOFV of â107.8 and ÎAIC of â101.8 for FTC). With statistical criteria as well as GOF plots, FTC was best described by a 2âcompartment model with firstâorder absorption and elimination. The addition of absorption lag time further reduced the objective function (ÎOFV of 33.0 for FTC) and improved the fit of the observations in the absorption phase. It was found that parent FTC was best linked with intracellular FTCâTP by firstâorder formation and elimination. Residual error was modelled using a proportional error model. CrCl calculated using female correction factor for TGW was shown to be a significant covariate on clearance (ÎOFV of â11.7). Gender and CrCl were colinear. Based on biological plausibility, CrCl was included in the model. In a sequential step, gender was tested as a covariate in addition to CrCl, but was not a significant covariate. Inclusion of CrCl as a covariate reduced the betweenâsubject variability (BSV; %CV) on CL to 7.5% from 12.9% in the base model. A schematic of the model is shown in FigureÂ <xref rid="bcp15310-fig-0001" ref-type="fig">1</xref>. The intracellular halfâlife for FTCâTP was calculated as 15âhours.</p>
                <fig position="float" fig-type="FIGURE" id="bcp15310-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Model schematic for tenofovir disoproxil fumarate and emtricitabine disposition. k<sub>a</sub>, absorption rate constant; ALAG, lag time; CL, clearance from the central compartment; V2, central compartment volume of distribution; V4, peripheral compartment volume of distribution; Q1, intercompartmental clearance; K23, formation rate constant of metabolite stimulated by plasma drug; K30, elimination rate constant of intracellular metabolite</p>
                  </caption>
                  <graphic xlink:href="BCP-88-3674-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>The percent relative standard error (%RSE) of the PK parameter estimates was acceptable with &lt;30% for fixed effect parameters and residual error, and &lt;65% for random effects. The shrinkage was &lt;30% for all random effects parameters that were estimated on absorption rate constant, except BSV (37% shrinkage). GOF plots of the final model are shown in FigureÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S2</xref>. These plots showed no major bias and were considered acceptable. The VPC plot represented in FigureÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S3</xref> indicated a good predictive performance of the model showing an agreement between the distribution of observed and predicted data. Final parameters along with bootstrap 95% confidence intervals (CIs) are provided in TableÂ <xref rid="bcp15310-tbl-0002" ref-type="table">2</xref>.</p>
                <table-wrap position="float" id="bcp15310-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Emtricitabine and emtricitabine triphosphate population pharmacokinetic parameter estimates for the final models and bootstrap results for the final model</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="2" valign="bottom" colspan="1">Parameter (unit)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Final model</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Bootstrap</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Estimate (% RSE)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Median (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Fixed effects</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">k<sub>a</sub> (1/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.10 (20)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.95 (1.09â32.32)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V2 (L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">76.1 (6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">71.7 (51.7â83.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V4 (L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">77.9 (13)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">70.5 (55.6â108.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Q1 (L/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7.89 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9.07 (5.95â15.22)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CL (L/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19.8 (3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19.2 (16.7â21.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ALAG (h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.522 (26)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.464 (0.005â0.979)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">K30 (1/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.69E<sup>â2</sup> (13)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.78E<sup>â2</sup> (1.82E<sup>â2</sup>â8.50E<sup>â2</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">K23 (1/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.08E<sup>â2</sup> (15)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.16E<sup>â2</sup> (4.20E<sup>â3</sup>â2.96E<sup>â2</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Covariate effect</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CrCl on CL<xref rid="bcp15310-note-0004" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.96E<sup>â2</sup> (18)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.12E<sup>â1</sup> (1.76E<sup>â1</sup>â4.63E<sup>â1</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Interindividual variability (%CV)</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">k<sub>a</sub>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">139.6 (33)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">112.1 (36.5â235.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ALAG</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">65.3 (65)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">78.0 (0.7â361.8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Q1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42.3 (53)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">27.3 (0.4â68.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CL</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7.5 (51)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.5 (0.1â12.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">K30</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">28.5 (34)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25.8 (7.3â36.0)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Residual variability (% CV)</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportional error on parent</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18.3 (18)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17.9 (13.5â22.7)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportional error on metabolite</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">43.4 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42.6 (30.3â56.7)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="bcp15310-ntgp-0002">
                    <fn id="bcp15310-note-0004">
                      <label>*</label>
                      <p>
                        <mml:math id="jats-math-2" display="inline" overflow="scroll">
                          <mml:msub>
                            <mml:mi>CL</mml:mi>
                            <mml:mtext>individual</mml:mtext>
                          </mml:msub>
                          <mml:mo linebreak="goodbreak">=</mml:mo>
                          <mml:msub>
                            <mml:mi>CL</mml:mi>
                            <mml:mtext>population</mml:mtext>
                          </mml:msub>
                          <mml:mo linebreak="goodbreak">Ã</mml:mo>
                          <mml:msup>
                            <mml:mfenced open="(" close=")">
                              <mml:mfrac bevelled="true">
                                <mml:msub>
                                  <mml:mtext>CrCl</mml:mtext>
                                  <mml:mtext>individual</mml:mtext>
                                </mml:msub>
                                <mml:msub>
                                  <mml:mtext>CrCl</mml:mtext>
                                  <mml:mtext>median</mml:mtext>
                                </mml:msub>
                              </mml:mfrac>
                            </mml:mfenced>
                            <mml:mtext>CrClonCl</mml:mtext>
                          </mml:msup>
                          <mml:mo linebreak="goodbreak">Ã</mml:mo>
                          <mml:msup>
                            <mml:mi mathvariant="normal">e</mml:mi>
                            <mml:msub>
                              <mml:mi>BSV</mml:mi>
                              <mml:mi>Cl</mml:mi>
                            </mml:msub>
                          </mml:msup>
                        </mml:math>
                      </p>
                    </fn>
                    <fn id="bcp15310-note-1004">
                      <p>Abbreviations: ALAG, lag time; CL, clearance; CrCl, creatinine clearance; K23, formation rate of constant of metabolite stimulated by plasma drug; K30, elimination rate constant of intracellular metabolite; k<sub>a</sub>, absorption rate constant; Q1, intercompartmental clearance; V2, central compartment volume of distribution; V4, peripheral compartment volume of distribution.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="bcp15310-sec-0017">
                <label>3.3</label>
                <title>PopPK model of TFV and TFVâDP</title>
                <p>A decrease in objective function and AIC, and an improvement in GOF plots were observed in plasma TFV when comparing 1â and 2âcompartment models (ÎOFV of â133.9 and ÎAIC of â127.9 for TFV). A 2âcompartment model with firstâorder absorption best described plasma TFV concentration. After TFVâDP was linked to the plasma compartment with the firstâorder formation by the simultaneous estimation approach, higher interindividual variability, RSE and correlation of the parameters (K23 â K32 and K30 â ALAG with 0.95 and 0.90, respectively) were observed. The shrinkage was &lt;30% for all random effects parameters that were estimated. The implementation of nonlinear metabolite formation using the indirect response model approach<xref rid="bcp15310-bib-0016" ref-type="bibr"><sup>16</sup></xref> to describe plasma TFV and PBMC TFVâDP concentrations failed to converge. The sequential estimation approach showed similar PK parameter estimates when compared to the simultaneous approach. Gender and CrCl were significant covariates on CL when testing with a forward inclusion step (ÎOFV of â5.2 for gender and ÎOFV of â10.2 for CrCl). Following backward elimination, CrCl was a significant covariate of CL. Inclusion of CrCl as a covariate reduced the BSV (%CV) on CL to 18.6% from 31.2% in the base model. Residual error was modeled using a proportional error model. Final parameters along with 95% bootstrap CIs are provided in TableÂ <xref rid="bcp15310-tbl-0003" ref-type="table">3</xref>. A schematic of the model is shown in FigureÂ <xref rid="bcp15310-fig-0001" ref-type="fig">1</xref>. The intracellular halfâlife for TFVâDP was estimated as 173âhours.</p>
                <table-wrap position="float" id="bcp15310-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Tenofovir and tenofovir diphosphate population pharmacokinetic parameter estimates for the final models and bootstrap results for the final model</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="2" valign="bottom" colspan="1">Parameter (unit)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Final model</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Bootstrap</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Estimate (% RSE)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Median (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Fixed effects</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">k<sub>a</sub> (1/h)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 FIXED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 FIXED</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V2 (L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">234 (38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">234 (74â332)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V4 (L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">657 (92)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">656 (489â848)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Q1 (L/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">227 (27)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">227 (136â298)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CL (L/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">50 (13)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">50 (43â54)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ALAG (h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.290 (123)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.289 (0.003â0.403)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">K30 (1/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9.14E<sup>â3</sup> (303)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8.94E<sup>â3</sup> (9.14E<sup>â5</sup>â1.17E<sup>â2</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">K23 (1/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.03E<sup>â5</sup> (309)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.03E<sup>â5</sup> (2.00E<sup>â7</sup>â4.52E<sup>â5</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Covariate effect</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CrCl on CL<xref rid="bcp15310-note-0005" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5.97E<sup>â1</sup> (72)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5.89E<sup>â1</sup> (1.50E<sup>â1</sup>â8.74E<sup>â1</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Interindividual variability (%CV)</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">k<sub>a</sub>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">130.8 (789)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">130.5 (39.9â167.7)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CL</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18.6 (142)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18.6 (10.5â23.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22.6 (238)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22.1 (0.5â31.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">V4</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42.5 (155)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41.5 (3.7â47.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ALAG</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">114.0 (522)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">113.8 (77.2â307.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">
                          <italic toggle="yes">Residual variability (% CV)</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportional error on parent</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.7 (27)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.7 (11.7â18.3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportional error on metabolite</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">37.1 (70)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">37.1 (26.6â45.3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="bcp15310-ntgp-0003">
                    <fn id="bcp15310-note-0005">
                      <label>*</label>
                      <p>
                        <mml:math id="jats-math-3" display="inline" overflow="scroll">
                          <mml:msub>
                            <mml:mi>CL</mml:mi>
                            <mml:mtext>individual</mml:mtext>
                          </mml:msub>
                          <mml:mo linebreak="goodbreak">=</mml:mo>
                          <mml:msub>
                            <mml:mi>CL</mml:mi>
                            <mml:mtext>population</mml:mtext>
                          </mml:msub>
                          <mml:mo linebreak="goodbreak">Ã</mml:mo>
                          <mml:msup>
                            <mml:mfenced open="(" close=")">
                              <mml:mfrac bevelled="true">
                                <mml:msub>
                                  <mml:mtext>CrCl</mml:mtext>
                                  <mml:mtext>individual</mml:mtext>
                                </mml:msub>
                                <mml:msub>
                                  <mml:mtext>CrCl</mml:mtext>
                                  <mml:mtext>median</mml:mtext>
                                </mml:msub>
                              </mml:mfrac>
                            </mml:mfenced>
                            <mml:mtext>CrClonCl</mml:mtext>
                          </mml:msup>
                          <mml:mo linebreak="goodbreak">Ã</mml:mo>
                          <mml:msup>
                            <mml:mi mathvariant="normal">e</mml:mi>
                            <mml:msub>
                              <mml:mi>BSV</mml:mi>
                              <mml:mrow>
                                <mml:mi>Cl</mml:mi>
                                <mml:mo>.</mml:mo>
                              </mml:mrow>
                            </mml:msub>
                          </mml:msup>
                        </mml:math>
                      </p>
                    </fn>
                    <fn id="bcp15310-note-1005">
                      <p>Abbreviations: ALAG, lag time; CL, clearance; CrCl, creatinine clearance; K23, formation rate of constant of metabolite stimulated by plasma drug; K30, elimination rate constant of intracellular metabolite; k<sub>a</sub>, absorption rate constant; Q1, intercompartmental clearance; V2, central compartment volume of distribution; V4, peripheral compartment volume of distribution.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>GOF plots of the final model are shown in FigureÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S4</xref>. These plots showed no major bias. The VPC plot represented in FigureÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S5</xref> indicated a good predictive performance of the model showing an agreement between the distribution of observed and predicted data. Final parameters along with bootstrap 95% confidence intervals are provided in TableÂ <xref rid="bcp15310-tbl-0003" ref-type="table">3</xref>.</p>
              </sec>
              <sec id="bcp15310-sec-0018">
                <label>3.4</label>
                <title>Simulations of the conventional daily dose and onâdemand dosing</title>
                <p>Simulated continuous concentrationâtime profiles (FigureÂ <xref rid="bcp15310-fig-0002" ref-type="fig">2</xref>) and discrete C<sub>max</sub> and C<sub>min</sub> concentrations on day 3 and 10 (TableÂ <xref rid="bcp15310-supitem-0001" ref-type="supplementary-material">S1</xref>) for TFV, TFVâDP, FTC, and FTCâTP contrasted differences between daily and onâdemand PrEP, as well as differences between TGW and CGM. At all times over 2 weeks, PBMC TFVâDP concentrations after onâdemand dosing were below median steadyâstate concentrations with daily dosing consistent with expectations for 4 <italic toggle="yes">vs</italic>. 7 doses per week (18.8 <italic toggle="yes">vs</italic>. 36.3 fmol/10<sup>6</sup> cells); this was also observed for PBMC FTCâTP, although with far smaller differences (4 doses: 0.6âpmol/10<sup>6</sup> cells; 7 doses: 2.2âpmol/10<sup>6</sup> cells). The highest trough (C<sub>min</sub>) and peak (C<sub>max</sub>) PBMC TFVâDP concentrations during onâdemand dosing were 44 and 52% of daily dosing concentrations in week 1 (occurring on day 3) and increased to 63 and 67% of daily dosing concentrations in week 2 (occurring on day 10) and thereafter, with pseudoâsteadyâstate achieved in week 2. Contrasting TGW and CGM with on demand dosing, the highest trough and peak PBMC TFVâDP concentrations in TGW were 83 and 84% of CGM during weeks 1 and 2. In TGW on an onâdemand regimen, the highest trough and peak PBMC TFVâDP concentrations were 38 and 43% of daily dosing steadyâstate concentrations in CGM during the first week (day 3), and improved to 53 and 55% in week 2 (day 10) and thereafter. With a far shorter halfâlife, the highest trough concentrations of PBMC FTCâTP in all weeks of onâdemand dosing were similar to steadyâstate daily dosing; onâdemand dosing in TGW yielded PBMC FTCâTP concentrations only 8% below CGM on the same onâdemand regimen.</p>
                <fig position="float" fig-type="FIGURE" id="bcp15310-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Simulated mean concentrationâtime profiles of (a) tenofovir (TFV), (b) TFVâdiphosphate (TFVâDP), (c) emtricitabine (FTC) and (d) FTCâtriphosphate (FTCâTP) on conventional daily dose and 2â+â1â+â1 dosing. Blue line represents exposure point. CGM, cisgender men; TGW, transgender women</p>
                  </caption>
                  <graphic xlink:href="BCP-88-3674-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="bcp15310-sec-0019">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>This report describes the generation of an F/TDF popPK model that specifically focuses on TGW and the application of drug exposure simulations that take into consideration different populations and dosing regimens. Further, these simulations reflect current, onâdemand modalities for F/TDF PrEP use. This work focuses on an atârisk population and aims to determine optimal dosing strategies in TGW to ensure drug exposures consistent with protection.</p>
              <p>We developed a joint parentâmetabolite popPK model describing plasma TFV/FTC and intracellular TFVâDP/FTCâTP based on both TGW on GAHT and CGM, which demonstrated the substantial influence of CrCl variability on drug clearance for both TFV and FTC. Our parameter estimate for the CrCl effect on drug clearance is generally in agreement with previous studies.<xref rid="bcp15310-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="bcp15310-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="bcp15310-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="bcp15310-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="bcp15310-bib-0028" ref-type="bibr"><sup>28</sup></xref> Because gender was associated with CrCl, and based on biological rationale of the influence of hormones on renal function, we included only CrCl in the final model.</p>
              <p>The use of the 0.85 correction factor recommended for females in the CockcroftâGault CrCl calculation results in a 15% decrease in calculated CrCl in TGW when compared to CGM. In the phase 1 clinical trial used for model generation, median CrCl was 174âmL/min and 108âmL/min in TGW and CGM, respectively. This represents a 61% increase in CrCl in TGW, which is not accounted for by the CockroftâGault female correction factor, or the statistically insignificant 15% higher median body weight that can also influence CrCl. As CrCl was calculated using the 0.85 multiplier for TGW, it is expected that the model parameters estimates would need to be reâestimated if any other multiplier is used. However, we anticipate that the conclusions of the simulations would remain similar. More direct measurement of glomerular filtration rate using other methods, such as iohexol clearance, would provide a more accurate covariate of TFV and FTC renal clearance.</p>
              <p>A 2âcompartment model with first order absorption and elimination best described TFV plasma PK. Final parameters are in general agreement with previous reports for TFV.<xref rid="bcp15310-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="bcp15310-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="bcp15310-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="bcp15310-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="bcp15310-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="bcp15310-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="bcp15310-bib-0027" ref-type="bibr"><sup>27</sup></xref> Metabolite formation rate constant (K23) is in reasonable agreement with our prior report, once we take into consideration the difference in units for metabolite compartment.<xref rid="bcp15310-bib-0014" ref-type="bibr"><sup>14</sup></xref> The elimination halfâlife for the metabolite estimate (calculated as 0.693/K30) from this report is higher than Burns <italic toggle="yes">et al</italic>.,<xref rid="bcp15310-bib-0014" ref-type="bibr"><sup>14</sup></xref> but consistent with prior publications, which ranged from 150Â to 180Â hours.<xref rid="bcp15310-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="bcp15310-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="bcp15310-bib-0031" ref-type="bibr"><sup>31</sup></xref> Potential sources of such variability across studies may include sampling time differences and limits of quantification used in metabolite measurements.</p>
              <p>Plasma FTC was best described as a 2âcompartment model with first order absorption and elimination. PK parameter estimates are in general agreement with previous reports.<xref rid="bcp15310-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="bcp15310-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="bcp15310-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="bcp15310-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="bcp15310-bib-0032" ref-type="bibr"><sup>32</sup></xref> Saturable functions for metabolite formation were not used, given only 1 dose level. The previous elimination halfâlife of FTCâTP was 17â36 hours<xref rid="bcp15310-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="bcp15310-bib-0034" ref-type="bibr"><sup>34</sup></xref>; however, a slightly shorter halfâlife of FTCâTP of 15Â hours was observed in this study.</p>
              <p>Several studies have shown that the use of F/TDF for PrEP with GAHT is associated with decreased plasma TFV/FTC concentrations.<xref rid="bcp15310-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="bcp15310-bib-0035" ref-type="bibr"><sup>35</sup></xref> Hiransuthikul <italic toggle="yes">et al</italic>. reported 12 and 18% reductions in AUC and trough concentration of plasma TFV in TGW using GAHT; however, the study did not evaluate plasma FTC or intracellular metabolite concentrations.<xref rid="bcp15310-bib-0011" ref-type="bibr"><sup>11</sup></xref> Cirrincione <italic toggle="yes">et al</italic>. reported a reduction of 24 and 14% AUC in plasma TFV and FTC, respectively, in TGW compared to historical controls; however, they reported significantly higher (&gt;2âfold higher) PBMC concentrations of metabolites in TGW.<xref rid="bcp15310-bib-0035" ref-type="bibr"><sup>35</sup></xref> Shieh <italic toggle="yes">et al</italic>. evaluated both plasma TFV/FTC along with their intracellular components. They reported a reduction of 27 and 24% in AUC for plasma TFV and FTC concentrations in TGW compared to CGM, respectively. A reduction of 24 and 12% in AUC for TFVâDP and FTCâTP, respectively, was reported in this study, although the observation was not statistically significant.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> The clinical data described by Shieh and colleagues were used to generate the models described in this manuscript.</p>
              <p>We conducted simulations to compare daily dosing and onâdemand dosing strategies as well as TGW and CGM in terms of TFV, FTC, TFVâDP, and FTCâTP exposure. As expected, the combination of fewer doses per week and the days long PBMC TFVâDP halfâlife resulted in lower concentrations with onâdemand dosing throughout the simulated dosing periods. Comparing the highest PBMC TFVâDP concentrations during the initial (week 1) 4âdose onâdemand F/TDF regimen, TGW and CGM achieved only 45 and 53% of the lowest steadyâstate daily dosing concentrations in CGM. In the second week and thereafter (at pseudoâsteadyâstate), peak onâdemand dosing TFVâDP concentrations increased to 57 and 69%; notably, PBMC TFVâDP concentration in TGW during the second week of a weekly onâdemand regimen catches up with CGM concentrations achieved in the first onâdemand dosing week. The IPERGAY and PREVENIR trials studied onâdemand 2â+â1â+â1âF/TDF dosing with most participants taking the regimen weekly. Both studies demonstrated low to nonexistent instances of PrEP failure.<sup>8</sup> In the original IPERGAY study, only a small number of participants reported taking the onâdemand regimen less than weekly, but there was no apparent difference in PrEP efficacy in this group.<xref rid="bcp15310-bib-0008" ref-type="bibr"><sup>8</sup></xref> In addition, because there are no studies of an on demand 2â+â1â+â1 regimen with lower F/TDF doses than those used in the largely CGM populations in IPERGAY and PREVENIR, we previously raised concern that the 24%â32% reduction in plasma TFV concentrations<xref rid="bcp15310-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> could reduce the efficacy of onâdemand regimens, though have no negative impact on daily regimens. Combined with the simulations performed here, this provides some level of reassurance that, at least in the second week of onâdemand dosing, F/TDF protection in TGW is likely to be as high as in the initial onâdemand week in CGM, despite the observed impact of GAHT on TFV and TFVâDP concentrations.<xref rid="bcp15310-bib-0012" ref-type="bibr"><sup>12</sup></xref> This is further reinforced by the simulations indicating minor differences in FTCâTP across gender and dosing conditions. An essential caveat, however, is that neither the relative importance of peaks or troughs on any given day of the onâdemand regimen, nor the relative contribution of TFVâDP and FTCâTP with the F/TDF fixed dose combination, are established.</p>
              <p>Our models have several limitations. First, poor precision was observed in parameter estimates due to the small dataset used for model building. Second, our models assume linear PK and simulations conducted in terms of accumulation of exposure. Third, the sampling times for TFVâDP in the study do not ensure true steadyâstate conditions; therefore, this limits the accumulation ratio estimate; however, we do not believe this limitation impacts the overall findings of the described work. Extrapolation of models beyond this PrEP formulation is not ideal and should be carefully considered. This present study serves as an important starting point to explore an alternative regimen for TGW to help clinical study designs. Further validation of models is required before clinical implementation for alternative dosing decisions. Lastly, TFV alafenamide, which has very different blood and tissue TFVâDP PK when compared to TDF, requires its own models and simulations.</p>
            </sec>
            <sec sec-type="conclusions" id="bcp15310-sec-0020">
              <label>5</label>
              <title>CONCLUSIONS</title>
              <p>Joint popPK models for describing TFV/FTC and TFVâDP/FTCâTP concentrations after orally administered F/TDF in TGW have been developed and described in this report. Simulations indicate the onâdemand regimen requires 2 weekly 2â+â1â+â1âcycles in TGW on GAHT to ensure achievement of similar PBMC TFVâDP concentrations observed during the initial 2â+â1â+â1 regimen in CGM. Further, the 2â+â1â+â1 regimen in CGM, proven highly effective as PrEP, protects with only 1/2 to 2/3 of the TFVâDP concentrations associated with daily dosing.</p>
            </sec>
            <sec id="bcp15310-sec-0021">
              <title>COMPETING INTEREST</title>
              <p>M.A.M., E.J.F. and C.W.H. receive funded research support from Gilead Sciences, Merck and ViiV Healthcare. C.W.H. sits on a scientific advisory board for Merck. E.J.F. and C.W.H. are founders and officers of Prionde Biopharma. The other authors note no conflicts of interest.</p>
            </sec>
            <sec sec-type="conclusions" id="bcp15310-sec-0022">
              <title>CONTRIBUTORS</title>
              <p>C.W.H., E.J.G., E.S., R.P.B. and M.A.M. performed the original research study. A.T., A.C., C.W.H. and M.A.M. designed this research study. A.T. and A.C. developed the models and performed simulations. A.T., A.C., C.W.H. and M.A.M. drafted and edited manuscript. All authors read successive versions of the manuscript and approved the final manuscript.</p>
            </sec>
            <sec id="bcp15310-sec-0025">
              <title>STUDY PI DECLARATION</title>
              <p>The authors confirm that the PI for this paper is Mark Marzinke, PhD. The authors also claim that the PI for the clinical study in which these data are based upon is Craig Hendrix, MD, and that he had direct clinical responsibility for patients.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="bcp15310-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>FIGURE S1</bold> Comparison of gender <italic toggle="no">vs</italic>. CrCl.</p>
                  <p><bold>FIGURE S2</bold> Goodnessâofâfit plots of the final plasma FTC and PBMC FTCâTP models. (a, e) Individualâpredicted concentrations (IPRED) against observed concentrations (DV), (b, f) Populationâpredicted concentrations (PRED) against DV, (c, g) Time after dose against conditional weighted residuals (CWRES), and (d, h) PRED against CWRES.</p>
                  <p><bold>FIGURE S3</bold> Visual predictive check (VPC) for (a) plasma FTC and (b) PBMC FTC concentrations <italic toggle="no">vs</italic>. time. The dashed black and solid black lines depict the 5th, 50th and 95th percentiles of the observed and simulated concentrations, respectively. The shaded area represents the 95% confidence interval around the simulated percentiles.</p>
                  <p><bold>FIGURE S4</bold> Goodnessâofâfit plots of the final plasma TFV and PBMC TFVâDP models. (a, e) Individualâpredicted concentrations (IPRED) against observed concentrations (DV), (b, f) Populationâpredicted concentrations (PRED) against DV, (c, g) Time after dose against conditional weighted residuals (CWRES), and (d, h) PRED against CWRES.</p>
                  <p><bold>FIGURE S5</bold> VPC for (a) plasma TFV and (b) PBMC TFV concentrations <italic toggle="no">vs</italic>. time. The dashed black and solid black lines depict the 5th, 50th, and 95th percentiles of the observed and simulated concentrations, respectively. The shaded area represents the 95% confidence interval around the simulated percentiles.</p>
                  <p><bold>TABLE S1</bold> Simulated concentrations of intracellular metabolites for various dosing regimen of TDF/FTC</p>
                </caption>
                <media xlink:href="BCP-88-3674-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="bcp15310-sec-0023">
              <title>ACKNOWLEDGEMENTS</title>
              <p>We thank the study participants for their essential contributions to the clinical research that formed this basis of the described model. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins CFAR or NIH.</p>
              <p>This work was supported by the and National Institutes of Health, National Institute of Allergy and Infectious Diseases under award number R01 AI145675 (Principal Investigator: Marzinke). In addition, data generated during the phase 1 study were supported, in part, by the Johns Hopkins Center for AIDS Research through a developmental research grant (P30 AI042855; Principal Investigator: Hendrix) and the Clinical Pharmacology Training Program grant (Dr. Shieh, T32 GM066691).</p>
            </ack>
            <sec sec-type="data-availability" id="bcp15310-sec-0027">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study may be available from the corresponding author upon reasonable request and in compliance with relevant institutional policies.</p>
            </sec>
            <ref-list id="bcp15310-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="bcp15310-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0002"><string-name><surname>Baral</surname><given-names>SD</given-names></string-name>, <string-name><surname>Poteat</surname><given-names>T</given-names></string-name>, <string-name><surname>StrÃ¶mdahl</surname><given-names>S</given-names></string-name>, <string-name><surname>Wirtz</surname><given-names>AL</given-names></string-name>, <string-name><surname>Guadamuz</surname><given-names>TE</given-names></string-name>, <string-name><surname>Beyrer</surname><given-names>C</given-names></string-name>. <article-title>Worldwide burden of HIV in transgender women: a systematic review and metaâanalysis</article-title>. <source>Lancet Infect Dis</source>. <year>2013</year>;<volume>13</volume>(<issue>3</issue>):<fpage>214</fpage>â<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(12)70315-8</pub-id>
<pub-id pub-id-type="pmid">23260128</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0003"><string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Lau</surname><given-names>JTF</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, et al. <article-title>Acceptability of Daily Use of Free Oral Preâexposure Prophylaxis (PrEP) Among Transgender Women Sex Workers in Shenyang, China</article-title><source>AIDS Behav</source>. <year>2017</year>;<volume>21</volume>(<issue>12</issue>):<fpage>3287</fpage>â<lpage>3298</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10461-017-1869-4</pub-id>
<pub-id pub-id-type="pmid">28752354</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0004"><string-name><surname>Sevelius</surname><given-names>JM</given-names></string-name>, <string-name><surname>Deutsch</surname><given-names>MB</given-names></string-name>, <string-name><surname>Grant</surname><given-names>R</given-names></string-name>. <article-title>The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices</article-title>. <source>J Int AIDS Soc</source>. <year>2016</year>;<volume>19</volume>(<issue>7[Suppl 6]</issue>):<elocation-id>21105</elocation-id>. doi:<pub-id pub-id-type="doi">10.7448/IAS.19.7.21105</pub-id><pub-id pub-id-type="pmid">27760683</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0005"><string-name><surname>Tomlins</surname><given-names>L.</given-names></string-name><article-title>Prescribing for transgender patients</article-title>. <source>Aust Prescr</source>. <year>2019</year>;<volume>42</volume>(<issue>1</issue>):<fpage>10</fpage>â<lpage>13</lpage>. 10.18773/austprescr.2019.003. Epub 2019 Feb 1. Erratum in: Aust Prescr. 2019 Aug;42(4):145.<pub-id pub-id-type="pmid">30765903</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0006"><string-name><surname>Hamidi</surname><given-names>O</given-names></string-name>, <string-name><surname>DavidgeâPitts</surname><given-names>CJ</given-names></string-name>. <article-title>Transfeminine Hormone Therapy</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2019</year>;<volume>48</volume>(<issue>2</issue>):<fpage>341</fpage>â<lpage>355</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ecl.2019.02.001</pub-id>
<pub-id pub-id-type="pmid">31027544</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0007"><string-name><surname>Unger</surname><given-names>CA</given-names></string-name>. <article-title>Hormone therapy for transgender patients</article-title>. <source>Transl Androl Urol</source>. <year>2016</year>;<volume>5</volume>(<issue>6</issue>):<fpage>877</fpage>â<lpage>884</lpage>. doi:<pub-id pub-id-type="doi">10.21037/tau.2016.09.04</pub-id>
<pub-id pub-id-type="pmid">28078219</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="miscellaneous" id="bcp15310-cit-0008"><article-title>World Professional Association for Transgender Health Standards of Care for the Health of Transsexual Transgender, and Gender Nonconforming People, Version 7</article-title>.; <year>2010</year></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0009"><string-name><surname>Molina</surname><given-names>JM</given-names></string-name>, <string-name><surname>Capitant</surname><given-names>C</given-names></string-name>, <string-name><surname>Spire</surname><given-names>B</given-names></string-name>, et al. <article-title>OnâDemand Preexposure Prophylaxis in Men at High Risk for HIVâ1 Infection</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>23</issue>):<fpage>2237</fpage>â<lpage>2246</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1506273</pub-id>
<pub-id pub-id-type="pmid">26624850</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0010"><string-name><surname>Grant</surname><given-names>RM</given-names></string-name>, <string-name><surname>Lama</surname><given-names>JR</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>PL</given-names></string-name>, et al. <article-title>Preexposure chemoprophylaxis for HIV prevention in men who have sex with men</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>27</issue>):<fpage>2587</fpage>â<lpage>2599</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1011205</pub-id>
<pub-id pub-id-type="pmid">21091279</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0011"><string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Donnell</surname><given-names>D</given-names></string-name>, <string-name><surname>Ndase</surname><given-names>P</given-names></string-name>, et al. <article-title>Antiretroviral prophylaxis for HIV prevention in heterosexual men and women</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>(<issue>5</issue>):<fpage>399</fpage>â<lpage>410</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1108524</pub-id>
<pub-id pub-id-type="pmid">22784037</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0012"><string-name><surname>Hiransuthikul</surname><given-names>A</given-names></string-name>, <string-name><surname>Janamnuaysook</surname><given-names>R</given-names></string-name>, <string-name><surname>Himmad</surname><given-names>K</given-names></string-name>, et al. <article-title>Drugâdrug interactions between feminizing hormone therapy and preâexposure prophylaxis among transgender women: the iFACT study</article-title>. <source>J Int AIDS Soc</source>. <year>2019</year>;<volume>22</volume>(<issue>7</issue>):<elocation-id>e25338</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/jia2.25338</pub-id><pub-id pub-id-type="pmid">31298497</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0013"><string-name><surname>Shieh</surname><given-names>E</given-names></string-name>, <string-name><surname>Marzinke</surname><given-names>MA</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>EJ</given-names></string-name>, et al. <article-title>Transgender women on oral HIV preâexposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men</article-title>. <source>J Int AIDS Soc</source>. <year>2019</year>;<volume>22</volume>(<issue>11</issue>):<elocation-id>e25405</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/jia2.25405</pub-id><pub-id pub-id-type="pmid">31692269</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0014"><string-name><surname>Grant</surname><given-names>RM</given-names></string-name>, <string-name><surname>Pellegrini</surname><given-names>M</given-names></string-name>, <string-name><surname>Defechereux</surname><given-names>PA</given-names></string-name>, et al. <article-title>Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the iBrEATHe Study</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>:<elocation-id>ciaa1160</elocation-id>, <volume>73</volume>, <issue>7</issue>, <fpage>e2117</fpage>, <lpage>e2123</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1160</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0015"><string-name><surname>Burns</surname><given-names>RN</given-names></string-name>, <string-name><surname>Hendrix</surname><given-names>CW</given-names></string-name>, <string-name><surname>Chaturvedula</surname><given-names>A</given-names></string-name>. <article-title>Population pharmacokinetics of tenofovir and tenofovirâdiphosphate in healthy women</article-title>. <source>J Clin Pharmacol</source>. <year>2015</year>;<volume>55</volume>(<issue>6</issue>):<fpage>629</fpage>â<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcph.461</pub-id>
<pub-id pub-id-type="pmid">25581815</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0016"><string-name><surname>Duwal</surname><given-names>S</given-names></string-name>, <string-name><surname>SchÃ¼tte</surname><given-names>C</given-names></string-name>, <string-name><surname>von Kleist</surname><given-names>M</given-names></string-name>. <article-title>Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIVâ1 infection</article-title>. <source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>(<issue>7</issue>):<elocation-id>e40382</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0040382</pub-id><pub-id pub-id-type="pmid">22808148</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0017"><string-name><surname>Baheti</surname><given-names>G</given-names></string-name>, <string-name><surname>Kiser</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Havens</surname><given-names>PL</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>CV</given-names></string-name>. <article-title>Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIVâ1âinfected patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>11</issue>):<fpage>5294</fpage>â<lpage>5299</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.05317-11</pub-id>
<pub-id pub-id-type="pmid">21896913</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0018"><string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Seifert</surname><given-names>SM</given-names></string-name>, <string-name><surname>CastilloâMancilla</surname><given-names>JR</given-names></string-name>, et al. <article-title>Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates</article-title>. <source>PLoS ONE</source><year>2016</year>;<volume>11</volume>(<issue>11</issue>):<elocation-id>e0165505</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0165505</pub-id><pub-id pub-id-type="pmid">27832147</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0019"><string-name><surname>Garrett</surname><given-names>KL</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Maas</surname><given-names>BM</given-names></string-name>, et al. <article-title>A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2018</year>;<volume>367</volume>(<issue>2</issue>):<fpage>245</fpage>â<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1124/jpet.118.251009</pub-id>
<pub-id pub-id-type="pmid">30150483</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0020"><string-name><surname>Dumond</surname><given-names>JB</given-names></string-name>, <string-name><surname>Collins</surname><given-names>JW</given-names></string-name>, <string-name><surname>Cottrell</surname><given-names>ML</given-names></string-name>, et al. <article-title>p16<sup>INK4a</sup>, a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIVâInfected Subjects</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2017</year>;<volume>6</volume>(<issue>2</issue>):<fpage>120</fpage>â<lpage>127</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.12150</pub-id>
<pub-id pub-id-type="pmid">28019088</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0021"><string-name><surname>Simiele</surname><given-names>M</given-names></string-name>, <string-name><surname>D'Avolio</surname><given-names>A</given-names></string-name>, <string-name><surname>Baietto</surname><given-names>L</given-names></string-name>, et al. <article-title>Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>6</issue>):<fpage>2976</fpage>â<lpage>2978</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01236-10</pub-id>
<pub-id pub-id-type="pmid">21402849</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0022"><string-name><surname>Mould</surname><given-names>DR</given-names></string-name>, <string-name><surname>Upton</surname><given-names>RN</given-names></string-name>. <article-title>Basic concepts in population modeling, simulation, and modelâbased drug developmentâpart 2: introduction to pharmacokinetic modeling methods</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2013</year>;<volume>2</volume>(<issue>4</issue>):<elocation-id>e38</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/psp.2013.14</pub-id><pub-id pub-id-type="pmid">23887688</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0023"><string-name><surname>Jonsson</surname><given-names>EN</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Automated covariate model building within NONMEM</article-title>. <source>Pharm Res</source>. <year>1998</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1463</fpage>â<lpage>1468</lpage>. doi:<pub-id pub-id-type="doi">10.1023/A:1011970125687</pub-id>
<pub-id pub-id-type="pmid">9755901</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0024"><string-name><surname>Bergstrand</surname><given-names>M</given-names></string-name>, <string-name><surname>Hooker</surname><given-names>AC</given-names></string-name>, <string-name><surname>Wallin</surname><given-names>JE</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Predictionâcorrected visual predictive checks for diagnosing nonlinear mixedâeffects models</article-title>. <source>AAPS J</source>. <year>2011</year>;<volume>13</volume>(<issue>2</issue>):<fpage>143</fpage>â<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1208/s12248-011-9255-z</pub-id>
<pub-id pub-id-type="pmid">21302010</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0025"><string-name><surname>Ette</surname><given-names>EI</given-names></string-name>, <string-name><surname>Onyiah</surname><given-names>LC</given-names></string-name>. <article-title>Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>. <year>2002</year>;<volume>27</volume>(<issue>3</issue>):<fpage>213</fpage>â24, <lpage>224</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF03190460</pub-id>
<pub-id pub-id-type="pmid">12365204</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0026"><string-name><surname>Hooker</surname><given-names>AC</given-names></string-name>, <string-name><surname>Staatz</surname><given-names>CE</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method</article-title>. <source>Pharm Res</source>. <year>2007</year>;<volume>24</volume>(<issue>12</issue>):<fpage>2187</fpage>â<lpage>2197</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11095-007-9361-x</pub-id>
<pub-id pub-id-type="pmid">17612795</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0027"><string-name><surname>CastilloâMancilla</surname><given-names>JR</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>JH</given-names></string-name>, <string-name><surname>Rower</surname><given-names>JE</given-names></string-name>, et al. <article-title>Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2013</year>;<volume>29</volume>(<issue>2</issue>):<fpage>384</fpage>â<lpage>390</lpage>. doi:<pub-id pub-id-type="doi">10.1089/aid.2012.0089</pub-id>
<pub-id pub-id-type="pmid">22935078</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0028"><string-name><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Goti</surname><given-names>V</given-names></string-name>, <string-name><surname>Chaturvedula</surname><given-names>A</given-names></string-name>, et al. <article-title>Population Pharmacokinetics of Tenofovir in HIVâ1âUninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>(<issue>9</issue>):<fpage>5379</fpage>â<lpage>5386</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00559-16</pub-id>
<pub-id pub-id-type="pmid">27353269</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0029"><string-name><surname>Dickinson</surname><given-names>L</given-names></string-name>, <string-name><surname>Yapa</surname><given-names>HM</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A</given-names></string-name>, et al. <article-title>Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>10</issue>):<fpage>6080</fpage>â<lpage>6086</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01441-15</pub-id>
<pub-id pub-id-type="pmid">26195515</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0030"><string-name><surname>Pruvost</surname><given-names>A</given-names></string-name>, <string-name><surname>Negredo</surname><given-names>E</given-names></string-name>, <string-name><surname>Benech</surname><given-names>H</given-names></string-name>, et al. <article-title>Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virusâinfected patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1907</fpage>â<lpage>1914</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.49.5.1907-1914.2005</pub-id>
<pub-id pub-id-type="pmid">15855513</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0031"><string-name><surname>Pruvost</surname><given-names>A</given-names></string-name>, <string-name><surname>Negredo</surname><given-names>E</given-names></string-name>, <string-name><surname>ThÃ©odoro</surname><given-names>FÌÌ</given-names></string-name>, et al. <article-title>Pilot pharmacokinetic study of human immunodeficiency virusâinfected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavirâritonavir</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>(<issue>5</issue>):<fpage>1937</fpage>â<lpage>1943</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01064-08</pub-id>
<pub-id pub-id-type="pmid">19273671</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0032"><string-name><surname>Hawkins</surname><given-names>T</given-names></string-name>, <string-name><surname>Veikley</surname><given-names>W</given-names></string-name>, <string-name><surname>St Claire</surname><given-names>RL</given-names><suffix>3rd</suffix></string-name>, <string-name><surname>Guyer</surname><given-names>B</given-names></string-name>, <string-name><surname>Clark</surname><given-names>N</given-names></string-name>, <string-name><surname>Kearney</surname><given-names>BP</given-names></string-name>. <article-title>Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving tripleânucleoside regimens</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2005</year>;<volume>39</volume>(<issue>4</issue>):<fpage>406</fpage>â<lpage>411</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.qai.0000167155.44980.e8</pub-id>
<pub-id pub-id-type="pmid">16010161</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0033"><string-name><surname>Greene</surname><given-names>SA</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Prince</surname><given-names>HMA</given-names></string-name>, et al. <article-title>Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen</article-title>. <source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>106</volume>(<issue>4</issue>):<fpage>821</fpage>â<lpage>830</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.1464</pub-id>
<pub-id pub-id-type="pmid">31002391</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0034"><string-name><surname>Anderson</surname><given-names>PL</given-names></string-name>, <string-name><surname>Kiser</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gardner</surname><given-names>EM</given-names></string-name>, <string-name><surname>Rower</surname><given-names>JE</given-names></string-name>, <string-name><surname>Meditz</surname><given-names>A</given-names></string-name>, <string-name><surname>Grant</surname><given-names>RM</given-names></string-name>. <article-title>Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection</article-title>. <source>J Antimicrob Chemother</source>. <year>2011</year>;<volume>66</volume>(<issue>2</issue>):<fpage>240</fpage>â<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkq447</pub-id>
<pub-id pub-id-type="pmid">21118913</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0035"><string-name><surname>Seifert</surname><given-names>SM</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Meditz</surname><given-names>AL</given-names></string-name>, et al. <article-title>Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2016</year>;<volume>32</volume>(<issue>10â11</issue>):<fpage>981</fpage>â<lpage>991</lpage>. doi:<pub-id pub-id-type="doi">10.1089/aid.2016.0008</pub-id>
<pub-id pub-id-type="pmid">27526873</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15310-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="bcp15310-cit-0036"><string-name><surname>Cirrincione</surname><given-names>LR</given-names></string-name>, <string-name><surname>Podany</surname><given-names>AT</given-names></string-name>, <string-name><surname>Havens</surname><given-names>JP</given-names></string-name>, et al. <article-title>Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy</article-title>. <source>J Antimicrob Chemother</source>. <year>2020</year>;<volume>75</volume>(<issue>5</issue>):<fpage>1242</fpage>â<lpage>1249</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkaa016</pub-id>
<pub-id pub-id-type="pmid">32065631</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
